RxDoctor Payments Data

Evan Newbolt, MD

Ophthalmology · Pine Bluff, ARNPI 1245468925

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 41.2% of the total.

$3,486in general payments, 2019–2025

Across 178 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alcon$626
  • Bausch & Lomb Americas Inc.$229
  • Sight Sciences, Inc.$107
  • Omeros Corporation$106
  • Amgen$104
  • plus $878 from 14 others

What the payments were for

  • Food & beverage$3,486100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,486 in reported general payments places this provider in the 85th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$578,336
Medicare patients
962
Services billed
4,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost106$47,766
CombiganBrimonidine Tartrate/Timolol71$24,340
RestasisCyclosporine26$24,028
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol87$11,478
RocklatanNetarsudil Mesylat/Latanoprost24$8,417
Latanoprost647$8,216
Prednisolone Acetate162$5,354
Brimonidine Tartrate139$4,924
Cyclosporine12$4,891
Travoprost39$3,622
MoxifloxacinMoxifloxacin Hcl93$3,108
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat237$2,968
Ketorolac Tromethamine87$2,449
Timolol Maleate148$1,347
Dorzolamide Hcl68$1,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis$1,436$96,134203 claims
Aerie Pharmaceuticals, Inc.Rocklatan$15$8,41724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 125 ophthalmology providers in Arkansas.

Other ophthalmology in Pine Bluff

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →